Synthetic securitisations and Europe’s capital sweetener

Regulator weighs high-quality label for synthetic deals, but without favourable capital treatment

Hit TV series Westworld features a futuristic theme park filled with synthetic humanoids programmed to act out specific roles in a story. The show asks the ethical question: should the synths be treated like humans?

European financial authorities are grappling with their own synthetic conundrum. Should balance sheet synthetic securitisations be treated like other, cash deals? Specifically, should they qualify for a regulatory label designed for high-quality securitisations, which lowers the

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: